Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today)

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Oct. 20, 2003

By Aaron Lorenzo

No Comments

Today's news in brief
BioWorld
BioWorld briefs for Jan. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 10, 2025
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...
Australia’s Celosia heads toward clinic with gene therapy for ALS
BioWorld
After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that...
Sangamo stock plunges as Pfizer leaves hemophilia partnership
BioWorld
Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.